TY - JOUR
T1 - Increase of arginine dimethylation correlates with the progression and prognosis of ALS
AU - Ikenaka, Kensuke
AU - Atsuta, Naoki
AU - Maeda, Yasuhiro
AU - Hotta, Yuji
AU - Nakamura, Ryoichi
AU - Kawai, Kaori
AU - Yokoi, Daichi
AU - Hirakawa, Akihiro
AU - Taniguchi, Akira
AU - Morita, Mitsuya
AU - Mizoguchi, Kouichi
AU - Mochizuki, Hideki
AU - Kimura, K.
AU - Katsuno, Masahisa
AU - Sobue, Gen
N1 - Publisher Copyright:
© American Academy of Neurology.
PY - 2019/4/16
Y1 - 2019/4/16
N2 - ObjectiveTo investigate whether arginine methylation is altered in patients with amyotrophic lateral sclerosis (ALS) and how it affects disease severity, progression, and prognosis.MethodsWe compared the immunoreactivity of protein arginine methyltransferase 1 (PRMT1) and its products, asymmetric dimethylated proteins (ASYM), in postmortem spinal cord. We also measured the concentrations of total l-Arginine and methylated arginine residues, including asymmetric dimethyl l-Arginine (ADMA), symmetric dimethyl arginine, and monomethyl arginine, in CSF samples from 52 patients with ALS using liquid chromatography-Tandem mass spectrometry, and we examined their relationship with the progression and prognosis of ALS.ResultsThe immunoreactivity of both PRMT1 (p < 0.0001) and ASYM (p = 0.005) was increased in patients with ALS. The concentration of ADMA in CSF was substantially higher in patients with ALS than in disease controls. The ADMA/l-Arginine ratio was correlated with the change of decline in the ALS Functional Rating Scale at 12 months after the time of measurement (r = 0.406, p = 0.010). A Cox proportional hazards model showed that the ADMA/l-Arginine ratio was an independent predictor for overall survival. Moreover, a high ADMA/l-Arginine ratio predicted poor prognosis, even in a group with normal percentage forced vital capacity.ConclusionThere was an enhancement of arginine dimethylation in patients with ALS, and the ADMA/l-Arginine ratio predicted disease progression and prognosis in such patients.
AB - ObjectiveTo investigate whether arginine methylation is altered in patients with amyotrophic lateral sclerosis (ALS) and how it affects disease severity, progression, and prognosis.MethodsWe compared the immunoreactivity of protein arginine methyltransferase 1 (PRMT1) and its products, asymmetric dimethylated proteins (ASYM), in postmortem spinal cord. We also measured the concentrations of total l-Arginine and methylated arginine residues, including asymmetric dimethyl l-Arginine (ADMA), symmetric dimethyl arginine, and monomethyl arginine, in CSF samples from 52 patients with ALS using liquid chromatography-Tandem mass spectrometry, and we examined their relationship with the progression and prognosis of ALS.ResultsThe immunoreactivity of both PRMT1 (p < 0.0001) and ASYM (p = 0.005) was increased in patients with ALS. The concentration of ADMA in CSF was substantially higher in patients with ALS than in disease controls. The ADMA/l-Arginine ratio was correlated with the change of decline in the ALS Functional Rating Scale at 12 months after the time of measurement (r = 0.406, p = 0.010). A Cox proportional hazards model showed that the ADMA/l-Arginine ratio was an independent predictor for overall survival. Moreover, a high ADMA/l-Arginine ratio predicted poor prognosis, even in a group with normal percentage forced vital capacity.ConclusionThere was an enhancement of arginine dimethylation in patients with ALS, and the ADMA/l-Arginine ratio predicted disease progression and prognosis in such patients.
UR - http://www.scopus.com/inward/record.url?scp=85063651285&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063651285&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000007311
DO - 10.1212/WNL.0000000000007311
M3 - Article
C2 - 30867270
AN - SCOPUS:85063651285
SN - 0028-3878
VL - 92
SP - E1868-E1877
JO - Neurology
JF - Neurology
IS - 16
ER -